Image
Journal Club

IBD Journal Club:

Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD

Suggested Readings

Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists.

Agrawal M, et al. Gastroenterology. 2021;161(1):47-65.

STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.

Turner D, et al. Gastroenterology. 2021;160(5):1570-1583.

A treat-to-target update in ulcerative colitis: a systematic review.

Ungaro R, et al. Am J Gastroenterol. 2019;114(6):874-883.

From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting.

Mumolo MG, et al. World J Gastroenterol. 2018;24(33):3681-3694.

The role of laboratory tests in Crohn’s disease.

Cappello M, Morreale GC. Clin Med Insights Gastroenterol. 2016;9:51-62.

Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis.

Sands BE, et al. N Engl J Med. 2019; 381(13):1215-1226.

Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease.

Patel H, et al. Crohn's Colitis 360. 2019;1(2):otz022.

Prediction of outcome of treatment of acute severe ulcerative colitis using principal component analysis and artificial intelligence.

Ghoshal UC, et al. JGH Open. 2020;4(5):889-897.

P025 Ozanimod efficacy, safety, and histology in patients with moderate-to-severe ulcerative colitis during induction in the phase 3 True North study.

Sandborn W, et al. Am J Gastroenterol. 2020;115(suppl 1):S6-S7.

FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions.

US Food and Drug Administration. 2021.

The safety of vedolizumab for ulcerative colitis and Crohn's disease.

Colombel JF, et al. Gut. 2017;66(5):839-851.

Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2/3 studies.

Sandborn WJ, et al. Inflamm Bowel Dis. 2021;27(7):994-1007.

Relevant Resources

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Hepatitis C is Curable

Got it? Treat it!

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

The Changing Landscape of IBD

Emerging Concepts in Patient Management

The Big (& Small) Picture of Nonalcoholic Steatohepatitis

Building Your Understanding to Combat a Growing Problem

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Trends and Updates in IBD

Appraising the Therapeutic Armamentarium in Moderate and Severe Disease

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Setting a Course for the Optimal Management of IBD

An Interactive Learning Experience

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients